Arcturus Therapeutics Holdings Inc. (ARCT) has experienced a substantial pullback in its share price, with the stock currently hovering around $25, representing a steep decline of over 40% from its 52-week high of $45 reached just earlier this month.
This global messenger RNA medicines company is focused on developing vaccines and therapeutics for infectious diseases and rare genetic disorders, leveraging its proprietary LUNAR platform. The lead investigational product is ARCT-810, a systemically delivered mRNA for Ornithine Transcarbamylase (OTC) Deficiency.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.